Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Program: Scientific Session
General Topic: Clinical

Bench to Bedside in the Diagnosis and Treatment of Lupus Nephritis

Monday, October 27, 2025
1:00 PM - 2:30 PM Central Time
CE: 1.5

    Moderator(s)

  • LS

    Lisa Sammaritano, MD

    Hospital for Special Surgery
    New York, NY, United States

    Disclosure(s): No financial relationships with ineligible companies to disclose

  • MC

    May Choi, MD;FRCPC;MPH

    University of Calgary
    Calgary, AB, Canada

    Disclosure(s): AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Celltrion: Consultant (Terminated, January 1, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, January 1, 2024); GlaxoSmithKlein(GSK): Consultant (Terminated, January 2, 2023); Mallickrodt Pharmaceuticals: Consultant (Terminated, January 2, 2023); MitogenDx: Consultant (Ongoing); Organon: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, January 1, 2024); Werfen: Consultant (Ongoing)

    • Session Coordinator(s)

  • AA

    Anca Askanase, MD, MPH

    Director
    Columbia University Medical Center
    New York, NY, United States

    Disclosure(s): Alumis: Advisor or Review Panel Member (Ongoing); Amgen: Advisor or Review Panel Member (Terminated, August 15, 2024); AstraZeneca: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Grant/Research Support (Ongoing); Genentech: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Idorsia: Grant/Research Support (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing); NKARTA: Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing); Sanofi: Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing)

This session will introduce participants to the new biomarkers in development for lupus nephritis (LN) and the application of the guidelines to the treatment of LN. We will demonstrate use of the 2024 LN guideline in practice with a case-based format, with emphasis on refractory cases. The session will describe how the new findings from the AMP program can be translated in practice and how guideline can be applied in the evolving landscape for novel therapies.

Learning Objectives:

  • To review data on novel biomarkers in the diagnosis and monitoring of LN
  • To understand the rationale behind and how to apply the new LLN guidelines to the care of patients with LN
  • To appreciate the nuances and differences in treatments between new onset, recurrent, and refractory LN

Presentations:

  • 1:00 PM - 1:30 PM Central Time
    Applying Learnings from the AMP Program into the Clinic

    Speaker: Andrea Fava, MD – Johns Hopkins University

  • 1:30 PM - 2:00 PM Central Time
    Applying the Guideline to the Treatment of Refractory LN

    Speaker: Maria Dall'Era, MD – UCSF

  • 2:00 PM - 2:30 PM Central Time
    Applying the Guideline to the Treatment of LN for Newly Available Treatments

    Speaker: Anca Askanase, MD, MPH – Columbia University Medical Center